Cover Image
市場調查報告書

QRxPharma Limited的產品平台分析

QRxPharma Limited - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 256092
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
QRxPharma Limited的產品平台分析 QRxPharma Limited - Product Pipeline Review - 2014
出版日期: 2014年06月15日 內容資訊: 英文 42 Pages
簡介

QRxPharma Limited是開發,銷售疼痛管理等產品的醫藥品企業。

本報告提供QRxPharma Limited的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

QRxPharma Limited的基本資料

QRxPharma Limited概要

  • 主要資訊
  • 企業資料

QRxPharma Limited:R&D概要

  • 主要的治療範圍

QRxPharma Limited:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

QRxPharma Limited:開發中產品概況

  • 最後階段的開發中產品
    • 申請末通過/被撤消產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

QRxPharma Limited:藥物簡介

  • (morphine + oxycodone) IR
  • (morphine + oxycodone)
  • (morphine + oxycodone) CR
  • Q-8008
  • Q-8009
  • T-9001
  • V-0801

QRxPharma Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

QRxPharma Limited:最近的開發平台趨勢

QRxPharma Limited:暫停中的計劃

QRxPharma Limited:企業發表

QRxPharma Limited:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04993CDB

Global Markets Direct's, 'QRxPharma Limited - Product Pipeline Review - 2014', provides an overview of the QRxPharma Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of QRxPharma Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of QRxPharma Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of QRxPharma Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the QRxPharma Limited's pipeline products

Reasons to buy

  • Evaluate QRxPharma Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of QRxPharma Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the QRxPharma Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of QRxPharma Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of QRxPharma Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of QRxPharma Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • QRxPharma Limited Snapshot
    • QRxPharma Limited Overview
    • Key Information
    • Key Facts
  • QRxPharma Limited - Research and Development Overview
    • Key Therapeutic Areas
  • QRxPharma Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • QRxPharma Limited - Pipeline Products Glance
    • QRxPharma Limited - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • QRxPharma Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • QRxPharma Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • QRxPharma Limited - Drug Profiles
    • (morphine + oxycodone) IR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (morphine + oxycodone)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (morphine + oxycodone) CR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Q-8008
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Q-8009
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • T-9001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • V-0801
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • QRxPharma Limited - Pipeline Analysis
    • QRxPharma Limited - Pipeline Products by Target
    • QRxPharma Limited - Pipeline Products by Route of Administration
    • QRxPharma Limited - Pipeline Products by Molecule Type
    • QRxPharma Limited - Pipeline Products by Mechanism of Action
  • QRxPharma Limited - Recent Pipeline Updates
  • QRxPharma Limited - Dormant Projects
  • QRxPharma Limited - Company Statement
  • QRxPharma Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • QRxPharma Limited, Key Information
  • QRxPharma Limited, Key Facts
  • QRxPharma Limited - Pipeline by Indication, 2014
  • QRxPharma Limited - Pipeline by Stage of Development, 2014
  • QRxPharma Limited - Monotherapy Products in Pipeline, 2014
  • QRxPharma Limited - Combination Treatment Modalities in Pipeline, 2014
  • QRxPharma Limited - Filing rejected/Withdrawn, 2014
  • QRxPharma Limited - Phase III, 2014
  • QRxPharma Limited - Phase II, 2014
  • QRxPharma Limited - Preclinical, 2014
  • QRxPharma Limited - Pipeline by Target, 2014
  • QRxPharma Limited - Pipeline by Route of Administration, 2014
  • QRxPharma Limited - Pipeline by Molecule Type, 2014
  • QRxPharma Limited - Pipeline Products by Mechanism of Action, 2014
  • QRxPharma Limited - Recent Pipeline Updates, 2014
  • QRxPharma Limited - Dormant Developmental Projects,2014
  • QRxPharma Limited, Subsidiaries

List of Figures

  • QRxPharma Limited - Pipeline by Top 10 Indication, 2014
  • QRxPharma Limited - Pipeline by Stage of Development, 2014
  • QRxPharma Limited - Combination Treatment Modalities in Pipeline, 2014
  • QRxPharma Limited - Pipeline by Top 10 Target, 2014
  • QRxPharma Limited - Pipeline by Top 10 Route of Administration, 2014
  • QRxPharma Limited - Pipeline by Top 10 Molecule Type, 2014
  • QRxPharma Limited - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top